Your browser doesn't support javascript.
loading
IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms.
Batista Liz, Joao Carlos; Genre, Fernanda; Pulito-Cueto, Verónica; Remuzgo-Martínez, Sara; Prieto-Peña, Diana; Márquez, Ana; Ortego-Centeno, Norberto; Leonardo, María Teresa; Peñalba, Ana; Narváez, Javier; Martín-Penagos, Luis; Belmar-Vega, Lara; Gómez-Fernández, Cristina; Miranda-Filloy, José A; Caminal-Montero, Luis; Collado, Paz; De Árgila, Diego; Quiroga-Colina, Patricia; Vicente-Rabaneda, Esther F; Triguero-Martínez, Ana; Rubio, Esteban; León Luque, Manuel; Blanco-Madrigal, Juan María; Galíndez-Agirregoikoa, Eva; Martín, Javier; Gualillo, Oreste; Blanco, Ricardo; Castañeda, Santos; González-Gay, Miguel A; López-Mejías, Raquel.
Afiliación
  • Batista Liz JC; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Genre F; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Pulito-Cueto V; Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Remuzgo-Martínez S; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Prieto-Peña D; Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Márquez A; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Ortego-Centeno N; Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Leonardo MT; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Peñalba A; Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Narváez J; Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, 18016 Granada, Spain.
  • Martín-Penagos L; Department of Medicine, Universidad de Granada, 18071 Granada, Spain.
  • Belmar-Vega L; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Gómez-Fernández C; Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Miranda-Filloy JA; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Caminal-Montero L; Division of Paediatrics, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Collado P; Division of Rheumatology, Hospital Universitario de Bellvitge, 08907 Barcelona, Spain.
  • De Árgila D; Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, 39008 Santander, Spain.
  • Quiroga-Colina P; Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL-REDINREN, 39008 Santander, Spain.
  • Vicente-Rabaneda EF; Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain.
  • Triguero-Martínez A; Division of Dermatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Rubio E; Division of Rheumatology, Hospital Universitario Lucus Augusti, 27003 Lugo, Spain.
  • León Luque M; Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
  • Blanco-Madrigal JM; Division of Rheumatology, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain.
  • Galíndez-Agirregoikoa E; Division of Dermatology, Hospital Universitario de La Princesa, 28006 Madrid, Spain.
  • Martín J; Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain.
  • Gualillo O; Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain.
  • Blanco R; Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, 28006 Madrid, Spain.
  • Castañeda S; Department of Rheumatology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • González-Gay MA; Department of Rheumatology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • López-Mejías R; Division of Rheumatology, Hospital Universitario de Basurto, 48013 Bilbao, Spain.
J Clin Med ; 11(19)2022 Sep 22.
Article en En | MEDLINE | ID: mdl-36233442
ABSTRACT
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: España